Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
26.55
-0.13 (-0.49%)
Dec 16, 2025, 1:31 PM EST - Market open
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $179.52M in the quarter ending September 30, 2025, with 6.49% growth. This brings the company's revenue in the last twelve months to $716.79M, up 3.14% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm)
$716.79M
Revenue Growth
+3.14%
P/S Ratio
1.69
Revenue / Employee
$907,330
Employees
790
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
| Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
| Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
| Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
| Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
| Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
| Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
| Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
| Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
| Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
| Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
| Dec 31, 2008 | 13.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PCRX News
- 13 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical - GlobeNewsWire
- 5 weeks ago - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business - PRNewsWire
- 5 weeks ago - Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance - GlobeNewsWire
- 5 weeks ago - Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee - GlobeNewsWire
- 6 weeks ago - Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control - GlobeNewsWire